AIM ImmunoTech Inc.

AIM ImmunoTech Inc. announced a $2.4 million financing consisting of a registered direct offering of 7.5 million shares at $0.325 per share and concurrent private placement of Series I Warrants to purchase 15 million shares. The company plans to use proceeds for manufacturing clinical drug supply, Phase 3 clinical trial activities, and working ca...

AIM ImmunoTech Inc. disclosed that its 2025 audited financial statements contain a going concern emphasis of matter from its independent auditors. Despite this, management expressed confidence in its ability to raise funds based on positive progress in Phase 2 clinical trials of its lead drug Ampligen combined with AstraZeneca's Imfinzi for treat...

AIM ImmunoTech stock surged 73.66% to $1.21 after securing full approval for a Japanese patent protecting the use of Ampligen combined with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer. The patent extends through December 2039, strengthening the company's intellectual property position in a major global pharmaceutica...

AIM ImmunoTech Inc. announced the closing of its rights offering, which raised approximately $1.8 million. The offering allowed investors to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants. The company is focused on developing Ampligen (rintatolimod) for treating late-stage pancreatic c...

AIM ImmunoTech announced the expiration of its rights offering on March 3, 2026, which generated approximately $1.8 million in gross proceeds. The offering allowed shareholders to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants at $1,000 per unit. The company expects the offering to clo...